Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men

James R Marshall, Raymond F Burk, Rochelle Payne Ondracek, Kristina E Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George, Raymond Bergan, James R Marshall, Raymond F Burk, Rochelle Payne Ondracek, Kristina E Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George, Raymond Bergan

Abstract

According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer. The agent tested by SELECT, pure SEMET, could have been different from the selenized yeast tested in NPC. One of the selenium forms suspected of having chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine (MSC). This study, with 29 selenium-replete patients enrolled in a randomized, double-blind trial, compared the multiple-dose toxicity, pharmacokinetics and pharmacodynamics of MSC and SEMET. Patients were on trial for 84 days. No toxicity was observed. Although SEMET supplementation increased blood selenium concentration more than MSC did, neither form had a more than minimal impact on the two major selenoproteins: selenoprotein P(SEPP1) and glutathione peroxidase(GPX).

Keywords: chemoprevention; methyl selenocysteine; pharmacokinetics; selenium; selenomethionine.

Conflict of interest statement

CONFLICTS OF INTEREST

None.

Figures

Figure 1. Phase 1 Multiple Dose Study…
Figure 1. Phase 1 Multiple Dose Study of 12-week treatment by Se=Methyl-L-Selenocysteine (MSC) and L-Selenomethionine (SEMET) in adult males

References

    1. Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids. Journal of the American Dietetic Association. 2000;100:637–640.
    1. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998;90:1219–1224.
    1. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001;166:2034–2038.
    1. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000;92:2018–2023.
    1. Clark LC, Combs GF, Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr, Park HK, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama. 1996;276:1957–1963.
    1. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU international. 2003;91:608–612.
    1. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Jr, Slate EH, Fischbach LA, Marshall JR, Clark LC. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer epidemiology, biomarkers & prevention. 2002;11:630–639.
    1. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF, Jr, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst. 2003;95:1477–1481.
    1. Karp DD, Lee SJ, Wright GLS, Johnson DH, Johnston MR, Goodman GE, Clamon GH, Okawara GS, Marks R, Ruckdeschel JC. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 2010;28(15_suppl):CRA7004–CRA7004.
    1. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, 3rd, Crawford ED, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) Jama. 2009;301:39–51.
    1. Marshall JR, Tangen CM, Sakr WA, Wood DP, Jr, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, et al. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer prevention research (Philadelphia, Pa) 2011;4:1761–1769.
    1. Uden PC, Totoe Boakye H, Kahakachchi C, Hafezi R, Nolibos P, Block E, Johnson S, Tyson JF. Element selective characterization of stability and reactivity of selenium species in selenized yeast. Journal of Analytical Atomic Spectrometry. 2004;19:65–73.
    1. Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer epidemiology, biomarkers & prevention. 2006;15:804–810.
    1. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106:djt456.
    1. Poerschke RL, Franklin MR, Moos PJ. Modulation of redox status in human lung cell lines by organoselenocompounds: selenazolidines, selenomethionine, and methylseleninic acid. Toxicol In Vitro. 2008;22:1761–1767.
    1. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. The Proceedings of the Nutrition Society. 2005;64:527–542.
    1. Das RK, Bhattacharya S. Anti-tumour promoting activity of diphenylmethyl selenocyanate against two-stage mouse skin carcinogenesis. Asian Pac J Cancer Prev. 2005;6:181–188.
    1. Gopalakrishna R, Gundimeda U. Antioxidant regulation of protein kinase C in cancer prevention. The Journal of nutrition. 2002;132:3819s–3823s.
    1. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res. 2001;61:7071–7078.
    1. Zhao R, Domann FE, Zhong W. Apoptosis induced by selenomethionine and methioninase is superoxide-mediated and p53-dependent in human prostate cancer cells. Molecular cancer therapeutics. 2006;5:3275–3284.
    1. Xiang N, Zhao R, Zhong W. Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells. Cancer chemotherapy and pharmacology. 2009;63:351–362.
    1. Richie JP, Das A, Calcagnotto AM, Sinha R, Neidig W, Liao J, Lengerich EJ, Berg A, Hartman TJ, Ciccarella A, Baker A, Kaag MG, Goodin S, et al. Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial. Cancer prevention research (Philadelphia, Pa) 2014;7:796–804.
    1. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 2000;60:2882–2886.
    1. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res. 2003;63:52–59.
    1. Patterson BH, Levander OA, Helzlsouer K, McAdam PA, Lewis SA, Taylor PR, Veillon C, Zech LA. Human selenite metabolism: a kinetic model. The American journal of physiology. 1989;257:R556–567.
    1. Swanson CA, Patterson BH, Levander OA, Veillon C, Taylor PR, Helzlsouer K, McAdam PA, Zech LA. Human [74Se]selenomethionine metabolism: a kinetic model. The American journal of clinical nutrition. 1991;54:917–926.
    1. Ip C, Birringer M, Block E, Kotrebai M, Tyson JF, Uden PC, Lisk DJ. Chemical Speciation Influences Comparative Activity of Selenium-Enriched Garlic and Yeast in Mammary Cancer Prevention. Journal of Agricultural and Food Chemistry. 2000;48:2062–2070.
    1. Ip C. Lessons from basic research in selenium and cancer prevention. The Journal of nutrition. 1998;128:1845–1854.
    1. Burk RF, Hill KE. Regulation of Selenium Metabolism and Transport. Annual review of nutrition. 2015;35:109–134.
    1. Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R. Methyl Selenocysteine: single-dose pharmacokinetics in men. Cancer prevention research (Philadelphia, Pa) 2011;4:1938–1944.
    1. Lee JI, Nian H, Cooper AJ, Sinha R, Dai J, Bisson WH, Dashwood RH, Pinto JT. Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer prevention research (Philadelphia, Pa) 2009;2:683–693.
    1. Pinto JT, Lee JI, Sinha R, MacEwan ME, Cooper AJ. Chemopreventive mechanisms of alpha-keto acid metabolites of naturally occurring organoselenium compounds. Amino acids. 2011;41:29–41.
    1. Pinto JT, Krasnikov BF, Alcutt S, Jones ME, Dorai T, Villar MT, Artigues A, Li J, Cooper AJL. Kynurenine Aminotransferase III, Glutamine Transaminase L Are Identical Enzymes that have Cysteine S-Conjugate β-Lyase Activity and Can Transaminate l-Selenomethionine. Journal of Biological Chemistry. 2014;289:30950–30961.
    1. Kang Y, Nian H, Rajendran P, Kim E, Dashwood WM, Pinto JT, Boardman LA, Thibodeau SN, Limburg PJ, Lohr CV, Bisson WH, Williams DE, Ho E, et al. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell death & disease. 2014;5:e1476.
    1. Ip C, Zhu Z, Thompson HJ, Lisk D, Ganther HE. Chemoprevention of mammary cancer with Se-allylselenocysteine and other selenoamino acids in the rat. Anticancer research. 1999;19:2875–2880.
    1. Ganther HE. Nutrition and Cancer Prevention: New Insights into the Role of Phytochemicals. Boston, MA: Springer US; 2001. Selenium Metabolism and Mechanisms of Cancer Prevention; pp. 119–130.
    1. Ohta Y, Suzuki KT. Methylation and demethylation of intermediates selenide and methylselenol in the metabolism of selenium. Toxicology and applied pharmacology. 2008;226:169–177.
    1. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxidants & redox signaling. 2007;9:775–806.
    1. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN. Characterization of mammalian selenoproteomes. Science (New York, NY) 2003;300:1439–1443.
    1. Lee BJ, Worland PJ, Davis JN, Stadtman TC, Hatfield DL. Identification of a selenocysteyl-tRNA(Ser) in mammalian cells that recognizes the nonsense codon UGA. The Journal of biological chemistry. 1989;264:9724–9727.
    1. Ip C, Marshall J, Park YM, Zhang H, Dong YAN, Wu YUE, Gao AC. CHAPTER 33 - Selenium and Cancer Prevention A2. In: Heber David., editor. Nutritional Oncology. Second. Burlington: Academic Press; 2006. pp. 573–581.
    1. Jackson MI, Combs GF., Jr Selenium and anticarcinogenesis: underlying mechanisms. Current opinion in clinical nutrition and metabolic care. 2008;11:718–726.
    1. McCormick D. Range Findings and Acute Oral Toxicity Studies of Chemopreventive Agents. 2002. Final Report for N01-CN-05130.
    1. McCormick D. Fourteen-day oral range finding studies and twenty-eight day oral toxicity studies in dogs: Selenomethyl-selenocysteine. 2003. Final Report for N01-CN-15140.
    1. Medina D, Thompson H, Ganther H, Ip C. Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutrition and cancer. 2001;40:12–17.
    1. Epplein M, Burk RF, Cai Q, Hargreaves MK, Blot WJ. A Prospective Study of Plasma Selenoprotein P, Lung Cancer Risk Among Low-Income Adults. Cancer epidemiology, biomarkers & prevention. 2014;23:1238–1244.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal of clinical oncology. 1982;5:649–655.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa